Alternative routes of insulin delivery

Journal of Central South University (Medical Sciences)

Volumn 34, Issue 10, 2009, Pages 933-948

  Krishnankutty, Ranjith K ^a   Mathew, Aju ^a   Sedimbi, Saikiran K ^a   Suryanarayan, Shrikumar ^b   Sanjeevi, Carani B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Biocon Limited   (India)

Author keywords

Alternative routes on insulin delivery; Buccal insulin; Nasal insulin; Oral insulin

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

BUCCAL DRUG ADMINISTRATION; DIABETES MELLITUS; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; METHODOLOGY; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, BUCCAL; ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; DIABETES MELLITUS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 70450220591     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Braunwald E, Fauci A S, Kasper D L, et al. Harrison'8 textbook of internal medicine [M]. 15 th ed. New York: McGraw Hill, 2001.
2. Reichard P, Nilsson B Y, Rosenqvist U. The effect of longterm intensified insulin treatment on the development of microvascular complications of diabetes mellitus [J]. N Engl J Med, 1993, 329 (5):304-309.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment on the development and progression of long-term complications in insulin - dependent diabetes mellitus [J]. N Engl J Med, 1993, 329 (14):977-986.
4. Writing team for DCCT/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus [J]. JAMA, 2002, 287 (19):2563-2569.
5. Garg A. Lipodystrophies [J]. Am J Med, 2000, 108 (2):143-152.
6. Hirsch I B. Insulin analogues [J]. N Engl J Med, 2005, 352 (2):174-183.
7. Chait A, Bierman E L. Pathogenesis of macrovascular disease in diabetes [M]//Kahn C R, Weir G C. Joslin's diabetes mellitus. 13 th ed. Lea & Febiger: Philadelphia, PA, 1994:648-664.
8. Del Prato S, Leonetti E, Simonson D C, et al. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man [J]. Diabetologia, 1994, 37 (10):1025-1035.
9. Woodyatt R T. The clinical use of insulin [J]. J Metab Res, 1922, 2:793-801.
10. Ilium L. Nasal delivery of peptides, factors affecting nasal absorption [M]//Crommelin D J, Midha K K. Topics in pharmaceutical sciences. Stuttgart: Medpharm Scientific, 1992:71-82.
11. Lee VHL, Kashi S D, Grass G M, et al. Oral route of peptide and protein drug delivery [M]//Lee V H. Peptide and protein drug delivery. New York: Marcel Decker, 1991:698-738.
12. Hashimoto M, Takada K, Kiso Y, et al. Synthesis of palmitoyl derivatives of insulin and their biological activities [J]. Pharm Res, 1989, 6(2):171-176.
13. Yokosuka T, Merkus F W, Schipper N G, et al. The influence of absorption enhancers on intranasal insulin absorption in normal and diabetic subjects [J]. J Control Release, 1996, 41:69-75.
14. Carey M C, Small D M. Micelle formation by bile salts [J]. Arch Intern Med, 1972, 130:506-527.
15. Gordon G S, Moses A C, Silver R D, et al. Nasal absorption of insulin: enhancement by hydrophobic bile salts [J]. Proc Natl Acad Sci USA, 1985, 82(21):7419-7423.
16. Uchida N, Maitani Y, Machida Y, et al. Influence of bile salts on the permeability of insulin through the nasal mucosa of rabbits in comparison with dextran derivatives [J]. Int J Pharm, 1991, 74:95-103.
17. Martin G P, Marriott C, Kellaway I W. Direct effect of bile salts and phospholipids on the physical properties of mucus [J]. Gut, 1978, 19(2):103-107.
18. Hirai S, Ikenaga T. Matsuzawa T. Nasal absorption of insulin in dogs [J]. Diabetes, 1978, 27(3):296-299.
19. Yokosuka T, Omori Y, Hirata Y, et al. Nasal and sublingual administration of insulin in man [J]. J Jpn Diabetes Soc, 1977, 20:146-152.
20. Hirata Y, Yokosuka T, Kasahara T, et al. Nasal administration of insulin in patients with diabetes [M]//Baba S, Kaneko T, Yanaihara C. Proceedings of the symposium on proinsulin, insulin and C-peptide. Amsterdam; Excerpta Medica, 1979:319-326.
21. Pontiroli A E, Alberetto M, Secchi A, et al. Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects [J]. Br Med J, 1982, 284(6321):303-306.
22. Frauman A G, Jerums G, Louis W J. Effects of intranasal insulin in non-obese type II diabetics [J]. Diabetes Res Clin Pract, 1987, 3(4):197-202.
23. Frauman A G, Cooper M E, Parsons B J, et al. Long-term use of intranasal insulin in insulin-dependent diabetic patients [J]. Diabetes Care, 1987, 10(5):573-578.
24. Moses A C, Gordon G S, Carey M C, et al. Insulin administered intranasally as an insulin-bile salt aerosol. Effectiveness and reproducibility in normal and diabetic subjects [J], Diabetes, 1983, 32(11):1040-1047.
25. Moses A C. Nasal absorption of insulin [J]. Pharm Weekbl, 1988, 10:45-46.
26. Nolte M S, Taboga C, Salamon E, et al. Biological activity of administered insulin in normal subjects [J]. Horm Metab Res, 1990, 22(3):170-174.
27. Pontiroli A E, Calderara A, Pozza G. Intranasal delivery: potential advantages and limitations from a clinical pharmacokinetic perspective [J]. Clin Phamacokinet, 1989, 17(5):209-307.
28. Frauman A G, Buchanan R, Jerums G, et al. Intranasal insulin (INI) treatment of type I diabetes: clinical and immunologic effects using two different absorption enhancing adjuvants [J]. Diabetes Res Clin Pract, 1988:S162-S174.
29. Hirai S, Yashiki T, Mima H. Mechanisms for the enhancement of the nasal absorption of insulin by surfactants [J]. Int J Pharm, 1981, 9:173-184. (Pubitemid 11021848)
30. Hersey S J, Jackson R T. Effect of bile salts on nasal permeability in vitro [J]. J Pharm Sci, 1987, 76(12):876-879.
31. Duchateau G S, Zuidema J, Merkus F W. Bile salts and intranasal drug absorption [J]. Int J Pharm, 1986, 31:193-199.
32. Hermens W A, Hooymans P M, Verhoef J C, et al. Effect of absorption enhancers on human nasal tissue ciliary movement in vitro [J]. Pharm Res, 1990, 7(2):144-146.
33. Florence A T, Attwood D. Physicochemical principles of pharmacy [M]. London: Macmillan, 1988.
34. Gibaldi M, Feldman S. Mechanisms of surfactant effects on drug absorption [J]. J Pharm Sci, 1970, 59(5):579-588.
35. Helenius A, Simons K. Solubilization of membranes by detergents [J]. Biochim Biophys Acta, 1975, 415(1):29-79.
36. Hirai S, Yashiki T, Mima H. Effect of surfactants on the nasal absorption of insulin in rats [J]. Int J Pharm, 1981, 9:165-172. (Pubitemid 11021847)
37. Salzman R, Manson J E, Grilling G T. Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type 1 diabetes [J]. N Engl J Med, 1985, 312(17):1078-1084.
38. Paquot N, Scheen A J, Franchimont P, et al. The intra - nasal administration of insulin induces significant hypoglycaemia and classical counter-regulatory responses in normal man [J]. Diabete Metabol, 1988, 14(1):31-36.
39. Lassmann-Vague V, Thiers D, Vialettes B, et al. Preprandial intranasal insulin [J]. Lancet, 1988, 1(8581):367-368.
40. Longenecker J P, Moses A C, Flier J S, et al. Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep [J]. J Pharm Sci, 1987, 76(5):351-355.
41. Daugherty A L, Liggitt H D, McCabe J G, et al. Absorption of recombinant methionyl - growth hormone (Met-hGH) from rat nasal mucosa [J]. Int J Pharm, 1988, 45:197-206.
42. Donovan M D, Flynn G L, Amidon G L. The molecular weight dependence of nasal absorption: the effect of absorption enhancers [J]. Pharm Res, 1990, 7(8):808-815.
43. Murakami T, Sasaki Y, Yamajo R, et al. Effect of bile salts on the rectal absorption of sodium ampicillin in rats [J]. Chem Pharm Bull, 1984, 32(5):1948-1955.
44. Cassidy M M, Tidball C S. Cellular mechanism of intestinal permeability alterations produced by chelation depletion [J]. J Cell Biol, 1967, 32(3):685-698.
45. Hinchcliffe M, Illum L. Intranasal insulin delivery and therapy [J]. Adv Drug Deliv Rev, 1999, 35(2-3):199-234.
46. Uchida N, Maitani Y, Machida Y, et al. Influence of bile salts on the permeability through the nasal mucosa of rabbits of insulin in comparison with dextran derivatives [J]. Drug Dev Ind Pharm, 1991, 17:1625-1634.
47. Critchley H. Intranasal drug delivery [D]. UK: University of Nottingham, 1989.
48. Aungst B J, Rogers N J. Site dependence of absorption promoting actions of laureth-9, sodium salicylate, disodium ED-TA, and aprotinin on rectal, nasal, and buccal insulin delivery [J]. Pharm Res, 1988, 5(5):305-308.
49. Hersey S J, Jackson R T. Effect of bile salts on nasal permeability in vitro [J]. J Pharm Sci, 1987, 76(12):876-879.
50. Mishima M, Wakita Y, Nakano M. Studies on the promoting effects of medium chain fatty acid salts on the nasal absorption of insulin in rats [J]. J Pharmacobiodyn, 1987, 10(11):624-631.
51. Jørgensen S, Drejer K. Insulin analogues and nasal insulin delivery [M]//Bailey C J, Flatt P R. New antidiabetic drugs. London; Smith - Gordon, 1990:83-92.
52. Drejer K, Vaag A, Bech K, et al, Intranasal administration of insulin with phospholipid as absorption enhancer: pharmacokinetics in normal subjects [J]. Diabetic Med, 1992, 9(4):335-340.
53. Jacobs M A, Schreuder R H, Jap-A-Joe K, et al. The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers [J]. Diabetes, 1993, 42(11):1649-1655.
54. Hilsted J, Madsbad S, Hvidberg A, et al. Intranasal insulin therapy: the clinical realities [J]. Diabetologia, 1995, 38(6):680-684.
55. Guldhammer B, Drejer K, Engesgaard A, et al. The absorption of intranasally administered insulin demonstrated by immunohistochemistry [J]. Diabetes Res Clin Pract, 1988, 5(Suppl1):A164.
56. Soerensen A R, Drejer K, Engesgaard A. Rabbit model for studies of nasal administration of insulin and glucagon [J]. Diabetes Res Clin Pract, 1988, 4(Suppl1):A165.
57. Irwin W J, Dwivedi A K, Holbrook P A, et al. The effect of cyclodextrins on the stability of peptides in nasal enzymic systems [J]. Pharm Res, 1994, 11(12):1698-1703.
58. Merkus F W, Verhoef J C, Romeijn S G, et al. Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats [J]. Pharm Res, 1991, 8(5):588-592.
59. Merkus F W, Schipper NGM, Verhoef J C. The influence of absorption enhancers on intranasal insulin absorption in normal and diabetic subjects [J]. J Control Release, 1996, 41:69-75.
60. Shao Z, Krishnamoorthy R, Mitra A K. Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations [J]. Pharm Res, 1992, 9(9):1157-1163.
61. Marttins E. Mechanistic studies in nasal drug delivery and absorption enhancement [D]. Leiden: University of Leiden, 1997.
62. Morimoto K, Morisaka K, Kamanda A. Enhancement of nasal absorption of insulin and calcitonin using polyacrylic acid gel [J]. J Pharm Pharmacol, 1985, 37(2):134-136. (Pubitemid 15162016)
63. [63.] Bjork E, Holmberg K, Bake B, et al. Effect of degradable starch microspheres on the human clearance [J]. Proc Int Symp Control Release Bioact Mater, 1992, 9:417-418.
64. Junginger H E. Bioadhesive polymer systems for peptide delivery [J]. Acta Pharm Technol, 1990, 36:110-126.
65. Dondeti P, Zia H, Needham T E. In vivo evaluation of spray formulations of human insulin for nasal delivery [J]. Int J Pharm, 1995, 122:91-105.
66. Bjork E, Edman P. Degradable starch microspheres as a nasal delivery system for insulin [J]. Int J Pharm, 1988, 47:233-238.
67. Farraj N F, Johansen B R, Davis S S, et al. Nasal administration of insulin using bioadhesive microspheres as a delivery system [J]. J Control Release, 1990, 13:253-261.
68. Artursson P. Epithelial transport of drugs in cell culture. I. A model for studying the passive diffusion of drugs intestinal absorptive (Caco-2) cells [J]. J Pharm Sci, 1990, 79:476-482. (Pubitemid 20221389)
69. Bjork E, Isaksson U, Edman P, et al. Starch microspheres induce pulsatile delivery of drugs and peptides across the epithelial barrier by reversible separation of the tight junctions [J]. J Drug Target, 1995, 2(6):501-507.
70. Bjork E, Holmberg K, Bake B, et al. Effect of degradable starch microspheres on the human mucociliary clearance [J]. Proc Int Symp Control Release Bioact Mater, 1992, 19:417-418.
71. Ilium L, Farraj N F, isher A N, et al. Hyaluronic acid ester microspheres as a nasal delivery system for insulin [J]. J Control Release, 1994, 29:133-141.
72. Roberts G A. Chitin chemistry [M]. London: Macmillan, 1992.
73. Ilium L, Farraj N F, Davis S S, Chitosan as a novel nasal delivery system for peptide drugs [J]. Pharm Res, 1994, 11:1186-1189.
74. Aspden T J. An evaluation of the potential use of chitosans in nasal peptide absorption systems [D]. UK: University of Nottingham, 1996.
75. Schipper N G, Olsson S, Hoogstraate J A, et al. Chitosans as absorption enhancers for poorly soluble drugs 2: Mechanism of absorption enhancement [J]. Pharm Res, 1997, 14(7):923-929.
76. Artursson P, Landmark T, Davis S S, et al. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2) [J]. Pharm Res, 1994, 11(9):1358-1361.
77. Dodane V, Khan M A, Merwin J R. Chitosan modulation of epithelial permeability and morphology [C]. Edinburgh: The Third European Congress of phamaceutical Sciences, 1996.
78. Heinemann L, Pftltzner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery [J]. Current Pharmaceutical Design, 2001, 7:1327-1351.
79. Guyton A C. Digestion and absorption in the gastrointestinal tract; gastrointestinal disorders [M]//Saunders W B. Human physiology and mechanisms of disease. 5 th ed. Philadelphia: W. B. Saunders, 1992:500-509.
80. Bai J P, Chang L L. Transepithelial transport of insulin: I. Insulin degradation by insulin - degrading enzyme in smallintestinal epithelium [J]. Pharm Res, 1995, 12(8):1171-1175.
81. Carino G P. Mathiowitz oral insulin delivery [J]. Adv Drug Deliv Rev, 1999, 35(2-3):249-257.
82. Olsen C L, Liu G, Charles A. Novel routes of insulin delivery [M]//Marshall S M, Home P D. The diabetes annual. Amsterdam, London, New York, Tokyo: Elsevier, 1994:243-276.
83. Mesiha M, Plakogiannis F, Vejosoth S. Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsions [J]. Int J Pharm, 1994, 111:213-216.
84. Fasano A, Fiorentini C, Donelli G, et al. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro [J]. J Clin Invest, 1995, 96(2):710-720.
85. Fasano A, Baudry B, Pumplin D W, et al. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions [J]. Proc Natl Acad Sci USA, 1991, 88(12):5242-5246.
86. Uzzau S, Fiore C R, Margaretten K T, et al. Modulation of intestinal tight junctions: a novel mechanism of intestinal secretion [J]. Gastroenterology, 1996, 110:370a.
87. Fasano A, Uzzau S. Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model [J]. J Clin Invest, 1997, 99(6):1158-1164.
88. Watts T L, Alexander T, Hansen B, et al. Utilizing the paracellular pathway: a novel approach for the delivery of oral insulin in diabetic rhesus macaques [J]. J Invest Med, 2000, 48:185.
89. Fasano A. Intestinal zonulin: open sesame! [J]. Gut, 2001, 49(2):159-162.
90. Touitou E, Rubinstein A. Targeted enteral delivery of insulin to rats [J]. Int J Pharm, 1986, 30:95-99.
91. Morishita M, Morishita I, Takayama K, et al. Site-dependent effect of aprotinin, sodium caprate, Na2 EDTA and sodium glycocholate on the intestinal absorption of insulin [J]. Biol Pharm Bull, 1993, 16(1):68-72.
92. Gwinup G, Elias A N, Domurat E S. Insulin and C-peptide levels following oral administration of insulin in intestinalenzyme protected capsules [J]. Gen Pharmacol, 1991, 22(2):243-246.
93. Yamamoto A, Taniguchi T, Rikyuu K, et al. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats [J]. Pharm Res, 1994, 11(10):1496-1500. (Pubitemid 24339662)
94. Hosny E A, Ghilzai NMK, Al-Dhawalie A H. Effective intestinal absorption of insulin in diabetic rats using enteric coated capsules containing sodium salicylate [J]. Drug Dev Ind Pharm, 1995, 21:1583-1589.
95. Ziv E, Lior O, Kidron M. Absorption of protein via the intestinal wall [J]. Biochem Pharm, 1987, 36(7):1035-1039.
96. Pappo J, Ermak T H. Uptake and translocation of fluorescent latex particles by rabbit Peyer' s patch follicle epithelium: a quantitative model for M cell uptake [J]. Clin Exp Immunol, 1989, 76(1):144-148.
97. Ermak T H, Dougherty E P, Bhagat H R, et al. Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells [J]. Cell Tissue Res, 1995, 279(2):433-436.
98. Hodges G M, Carr E A, Hazzard R A, et al. Uptake and translocation of microparticles in small intestine [J]. Dig Dis Sci, 1995, 40(5):967-975.
99. Damge C, Michel C, Aprahamian A, et al. Nanocapsules as carriers for oral peptide delivery [J]. J Control Release, 1990, 13:233-239.
100. Damge C, Michel C, Aprahamian A, et al. Advantage of a new colloidal drug delivery system in the insulin treatment of streptozotocin-induced diabetic rats [J]. Diabetologia, 1986, 29:531A.
101. Couvreur P, Lenaerts V, Kante B, et al. Speiseret, oral and parenteral administration of insulin associated to hydrolyzable nanoparticles [J]. Acta Pharm Tech, 1980, 26:220-222.
102. Mathiowitz E, Jacob J S, Jong Y S, et al. Biologically erodable microspheres as potential oral drug delivery systems [J]. Nature, 1997, 386(6623):410-414.
103. Gordon Still J. Development of oral insulin: progress and current status [J]. Diabetes Metab Res Rev, 2002, 18(Suppl1):S29-S37.
104. Clement S, Gordon Still J, Kosutic G, et al. Mcallister. Oral insulin product hexyl-insulin monoconjugate 2(HIM2) in Type 1 diabetes mellitus: the glucose stabilization effects of HIM2 [J]. Diab Tech Therapeut, 2002, 4(4):459-466.
105. Wajcberg E, Miyazaki Y, Triplitt C, et al. Dose - Response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects [J]. Diabetes Care, 2004, 27(12):2868-2873.
106. Kipnes M, Dandona P, Tripathy D, et al. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes [J]. Diabetes Care, 2003, 26(2):421-426.
107. Wan C K, Giacca A, Matsuhisa M, et al. Increased responses of glucagon and glucose production to hypoglycemia with intraperitoneal versus subcutaneous insulin treatment [J]. Metabolism, 2000, 49(8):984-989.
108. Gansslen M. Uber inhalation von insulin [J]. Klin Wochensubcutaneoushr, 1925, 4:71
109. Agu R U, Ugwoke M I, Armand M, et al. The lung as a route for systemic delivery of therapeutic proteins and peptides [J]. Respir Res, 2001, 2(4):198-209.
110. Heinemann L, Pfützner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery [J]. Current Pharmaceutical Design, 2001, 7(14):1327-1351.
111. Laube B L, Georgopoulus A, Adams G K. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients [J]. JAMA, 1993, 269(16):2106-2107.
112. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin [J]. ETIC Med, 1997, 14(1):63-72.
113. Fan S, McElduff A, Ward E, et al. The mode of inhalation influences the pharmacokinetics and pharmacodynamics of pulmonary delivered insulin in healthy fasted volunteers (abstract 1382) [J]. Pharm Res, 1997, 14(Suppl):S136.
114. Patton J S, Bukar J, Nagarajan S. Inhaled insulin [J]. Adv Drug Deliv Rev, 1999, 35(2-3):235-247.
115. Henry R R, Mudaliar S R, Chu N, et al. Inhaled insulin in young and elderly type 2 diabetic patients using the AERx diabetes management system: a pharmacokinetic and pharmacodynamic study [J]. EASD, 2002, 38:A812.
116. Himmelmann A, Jendle J, Mellen A et al. The impact of smoking on inhaled insulin [J]. Diabetes Care, 2003, 26(3):677-82.
117. Lehr H A. Microcirculatory dysfunction induced by cigarette smoking [J]. Microcirculation, 2000, 7(6 Pt1):367-384.
118. Schmekel B, Bos J A, Kahn R, et al. Integrity of the alveolar-capillary barrier and alveolar surfactant system in smokers [J]. Thorax, 1992, 47(8):603-608.
119. Becker R H, Sha S, Frick A D, et al. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin [J]. Diabetes Care, 2006, 29(2):277-282.
120. De Juan J A, Mova F J, Ripodas A, et al. Changes in the density and localisation of endothelin in the early stages of rat diabetic retinopathy and the efffect of insulin treatment [J]. Diabetologia, 2000, 43(6):773-785.
121. ®) comparison to subcutaneous insulin therapy in an intensive insulin regimen in patients with type 1 diabetes: results of a 6 - month, randomised comparative trial [J]. Diabetes, 2002, 51(Suppl2):A134.
122. Harrison R, Aye M, Morice A H, Inhaled insulin may be harmful in lung disease [J]. Diabetes, 2002, 51(Suppl2):A48.
123. Stoever J A, Palmer J P. Inhaled insulin and insulin antibodies: a new twist to an old debate [J]. Diabetes Technol Ther, 2002, 4(2):157-161.
124. Heise T, Tusek C, Stephan J A, et al. Insulin antibodies with inhaled insulin (Exubera): no evidence for impact on postprandial glucose control [J]. Diabetes, 2004, 64:463.
125. 2 EDTA, and aprotinin on rectal, nasal, and buccal insulin delivery [J]. Pharm Res, 1988, 5(5):305-308.
126. Hoogstraate J A, Wertz P W. Drug delivery via the buccal mucosa [J]. Pharmaceut Sci Technol Today, 1998, 1:309-316.
127. Veuillez F, Kalia Y N, Jacques Y, et al. Factors and strategies for improving buccal absorption of peptides [J]. Eur J Pharm Biopharm, 2001, 51(2):93-109.
128. Yang T Z, Wang X T, Yan X Y, et al. Phospholipid deformable vesicles for buccal delivery of insulin [J]. Chem Pharm Bull, 2002, 50(6):749-753.
129. Modi P, Mihic M, Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist System [J]. Diabetes Metab Res Rev, 2002, 18(Suppl1):S38-S42.
130. Guevara-Aguirre J, Guevara M, Saavedra J, et al. Beneficial effects of addition of oral spray insulin (oralin) on insulin secretion and metabolic control in subjects with Type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents [J]. Diabetes Technol Ther, 2004, 6(1):1-8.